Comparison of Double-Filtration Plasmapheresis and Plasma Exchange

Plasmapheresis is valuable in treating certain rheumatologic, oncologic, dermatologic, and renal diseases. In clinical practice, it is used to remove large-molecular-weight substances such as circulating immune complexes, endotoxins, and cholesterol-containing lipoproteins from plasma. Filtration plasmapheresis techniques target similar disease groups and have comparable indications. Double-filtration plasmapheresis (DFPP) is a specialised form of filtration that more selectively filters large molecules using two membranes: a plasma separator and a plasma fractionator. Depending on the physiochemical properties of the substance to be removed, an appropriate filter or adsorber material should be selected. DFPP is a safe, generally well-tolerated form of apheresis with efficacy comparable to plasma exchange, without the routine need for replacement blood products. Successful DFPP has been reported in individual cases of familial hypercholesterolemia, antiglomerular basement membrane disease, Guillain-Barré syndrome, and lupus nephritis. DFPP’s primary advantages include its lack of required replacement fluid, its ability to selectively separate plasma components, and its few side effects. However, limitations—such as procedural complexity and reimbursement issues—have restricted DFPP’s widespread use. In addition, few clinical studies have compared the efficacy of different plasmapheresis techniques. Randomised clinical trials are necessary to establish which method is most effective for specific diseases.